Histone deacetylase inhibitor but not arsenic trioxide differentiates acute promyelocytic leukaemia cells with t(11;17) in combination with all-trans retinoic acid

Br J Haematol. 2000 Mar;108(4):696-702. doi: 10.1046/j.1365-2141.2000.01933.x.

Abstract

Acute promyelocytic leukaemia (APL) with t(11;17)/PLZF-RARalpha responds poorly to all-trans retinoic acid (ATRA) and arsenic trioxide (As2O3), in contrast to APL with t(15;17)/PML-RARalpha. Molecular studies have shown that histone deacetylase (HDAC) recruited by PLZF-RARalpha is associated with the ATRA resistance. Here, we analysed in vitro the differentiation of APL cells with t(11;17) using ATRA, As203, granulocyte colony-stimulating factor (G-CSF), HDAC inhibitor trichostatin A (TSA), or combinations of these. Although 1 microM ATRA, which stimulated the differentiation of APL cells with t(15;17), was insufficient to induce differentiation, 3 microM ATRA induced terminal differentiation into granulocytes. As203 alone or in combination with ATRA induced neither differentiation nor apoptosis. However, the combination of TSA and 1 microM ATRA had a potent differentiating effect, although TSA alone had little effect. The combination of 1 microM ATRA and G-CSF did not induce differentiation. These results indicate that APL cells with t(11;17) need a higher concentration of ATRA than those with t(15;17) to differentiate and suggest that HDAC inhibitor is a promising differentiation enhancer in APL with t(11;17).

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Aged
  • Antineoplastic Agents / pharmacology
  • Antineoplastic Agents / therapeutic use*
  • Arsenic Trioxide
  • Arsenicals / pharmacology
  • Arsenicals / therapeutic use
  • Cell Differentiation / drug effects
  • Chromosomes, Human, Pair 11
  • Chromosomes, Human, Pair 17
  • Drug Therapy, Combination
  • Enzyme Inhibitors / therapeutic use*
  • Female
  • Histone Deacetylase Inhibitors*
  • Humans
  • Hydroxamic Acids / therapeutic use*
  • Leukemia, Promyelocytic, Acute / drug therapy*
  • Leukemia, Promyelocytic, Acute / genetics
  • Male
  • Oxides / pharmacology
  • Oxides / therapeutic use
  • Translocation, Genetic
  • Tretinoin / pharmacology
  • Tretinoin / therapeutic use*
  • Tumor Cells, Cultured / drug effects

Substances

  • Antineoplastic Agents
  • Arsenicals
  • Enzyme Inhibitors
  • Histone Deacetylase Inhibitors
  • Hydroxamic Acids
  • Oxides
  • trichostatin A
  • Tretinoin
  • Arsenic Trioxide